Spark Novartis Agreement

DisclaimerCe press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. “potentially,” “on,” “commitment,” “potential,” “potential,” “forward look,” “test time,” “current” or similar terms, or through explicit or tacit discussions about possible or tacit discussions about potential marketing authorizations, new indications or markings for neparvovec and other test and approval products described in this press release or potential future products. , or with respect to the licensing agreement and the production and supply agreement with Spark Therapeutics. You should not rely too much on these statements. These forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. If one or more of these risks or uncertainties arise or if the underlying assumptions prove to be incorrect, actual results may differ materially from those presented in the forward-looking statements. It cannot be guaranteed that any test or authorization product described in this press release may be submitted or approved for additional indications or markings in any market or at any given time. Nor can there be any guarantee that such products will be commercially successful in the future. Nor can there be any guarantee that Spark Therapeutics will successfully produce and deliver preliminary neparvovec under the production and delivery agreement, or in sufficient quantities or in a timely manner.

Nor can there be any guarantee that Novartis will successfully create new specialized treatment centres. Nor can there be any guarantee that we will achieve any of the objectives of the licensing, manufacturing and supply agreements, or that these agreements will be commercially successful. In particular, our expectations regarding the licensing agreement, the manufacturing and delivery agreement, the neparvovec and other test and licensing products described in this press release could be influenced, among other things, by regulatory measures or delays, or by public regulation in general; Spark Therapeutics` ability to successfully produce and supply neparvovec; research and development uncertainties, including clinical trial results and complementary analyses of existing clinical data; our ability to obtain or maintain intellectual property protection; Special prescription preferences of physicians and patients global trends in controlling health care costs, including public pressures on prices and public reimbursements, numerous and general; general economic and industrial conditions, including the effects of the continuing weakness of the economic and financial environment in many countries; Safety, quality or manufacturing issues potential or actual data security and data protection issues, as well as other risks and factors identified in Novartis AG`s current Form 20-F, which is available from the U.S. Securities and Exchange Commission. Novartis provides the information contained in this press release at this stage and undertakes no commitment to update any forward-looking statements contained in this press release based on new information, future events or otherwise.


Comments are closed.

Teisha Rowland, PhD, is the author of this blog.


  • No categories